Accrued expenses and other current liabilities consisted of (in thousands):


	September 30, 2024		December 31, 2023
Accrued compensation	$	2,840	$	4,046
Accrued contracted research and development costs		4,081		2,166
Accrued general and administrative costs		1,102		738
Lease liability		156		143
Total accrued expenses and other current liabilities	$	8,179	$	7,093

As of September 30, 2024, Accrued compensation includes amounts to be paid to employees for salary, bonuses, vacation and non-equity performance-based compensation. At the end of any period, the amounts accrued for such compensation may vary due to many factors including, but not limited to, timing of payments to employees and vacation usage.

As of September 30, 2024, Accrued contracted research and development costs are primarily comprised of costs associated with molgramostim for the treatment of aPAP, including expenses resulting from obligations under agreements with CROs, CMOs, and other outside service providers that provide services in connection with the Company's research and development activities.